Description
Vidalista (Tadalafil) 60 mg
Vidalista 60 mg is a product name used for a tablet containing tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. Tadalafil is an established prescription medicine used mainly for erectile dysfunction, and in some jurisdictions for other approved urologic indications. The exact trade name and local regulatory status of “Vidalista” should be verified separately from the active ingredient.
Active Ingredient and Medicine Class
The verified active ingredient is tadalafil. It belongs to the PDE5 inhibitor class. This class acts on the nitric oxide-cGMP pathway and is used to improve blood flow in erectile tissue.
Established Medical Uses
Tadalafil is established for the treatment of erectile dysfunction. Official prescribing information also includes approved use in some settings for benign prostatic hyperplasia or erectile dysfunction with BPH, depending on the product and market. Use for these conditions should be based on approved labeling in the relevant country.
How It Works
Tadalafil inhibits PDE5, an enzyme that breaks down cyclic guanosine monophosphate (cGMP). By preserving cGMP, it supports smooth-muscle relaxation and increased blood flow in the corpus cavernosum during sexual stimulation. Reviews of the clinical literature describe tadalafil as a long-acting PDE5 inhibitor with a prolonged therapeutic window.
Important Safety Information
Tadalafil is contraindicated with any form of organic nitrate because of the risk of marked blood pressure reduction. Prescribing information also warns about clinically important interactions with alpha-blockers, antihypertensive medicines, potent CYP3A4 inhibitors, and substantial alcohol intake. Patients with cardiovascular disease, recent major vascular events, severe hypotension, or certain eye or hearing disorders may require special caution according to product labeling.
Possible Side Effects
Common adverse effects reported with tadalafil include headache, dyspepsia, back pain, myalgia, nasal congestion, and flushing. Serious but less common reactions described in prescribing information include priapism, significant hypotension, sudden visual or hearing changes, and severe skin reactions.
Scientific Evidence
Peer-reviewed reviews and meta-analyses support tadalafil as an effective PDE5 inhibitor for erectile dysfunction across a range of severities and patient groups. Published evidence also describes its long duration of action and overall tolerability profile, with headache and dyspepsia among the most frequent adverse effects.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet, product labeling, or assessment by a qualified healthcare professional.
Medical Sources
- FDA — CIALIS (tadalafil) tablets, for oral use
- DailyMed — Tadalafil tablets, for oral use: Prescribing information
- Eric J H Meuleman, “Review of tadalafil in the treatment of erectile dysfunction,” Expert Opinion on Pharmacotherapy, 2003 — PubMed
